BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15000944)

  • 21. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
    J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation of hematologic parameters with bone marrow and spleen uptake in FDG PET].
    Núñez R; Rini JN; Tronco GG; Tomas MB; Nichols K; Palestro CJ
    Rev Esp Med Nucl; 2005; 24(2):107-12. PubMed ID: 15745681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the interval between G-CSF therapy and F-18 FDG PET imaging in children and young adults receiving chemotherapy for sarcoma.
    Trout AT; Sharp SE; Turpin BK; Zhang B; Gelfand MJ
    Pediatr Radiol; 2015 Jul; 45(7):1001-6. PubMed ID: 25646737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of diffusely increased splenic uptake on FDG-PET.
    Liu Y
    Nucl Med Commun; 2009 Oct; 30(10):763-9. PubMed ID: 19654562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging.
    Chiang SB; Rebenstock A; Guan L; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Aug; 28(8):674-6. PubMed ID: 12897658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological uptake of 18F-FDG in the vertebral bone marrow in healthy adults on PET/CT imaging.
    Shen G; Liang M; Su M; Kuang A
    Acta Radiol; 2018 Dec; 59(12):1487-1493. PubMed ID: 29486597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P
    Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation.
    Abdel-Dayem HM; Rosen G; El-Zeftawy H; Naddaf S; Kumar M; Atay S; Cacavio A
    Clin Nucl Med; 1999 May; 24(5):319-22. PubMed ID: 10232468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-FDG-PET/CT findings of granulocyte colony stimulating factor (G-CSF)-producing lung tumors.
    Morooka M; Kubota K; Murata Y; Shibuya H; Ito K; Mochizuki M; Akashi T; Chiba T; Nomura T; Ito H; Morita T
    Ann Nucl Med; 2008 Aug; 22(7):635-9. PubMed ID: 18756367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow.
    Elstrom RL; Tsai DE; Vergilio JA; Downs LH; Alavi A; Schuster SJ
    Clin Lymphoma; 2004 Jun; 5(1):62-4. PubMed ID: 15245610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma.
    Morgan R; Perry M; Kwak J; Jensen A; Kamdar M
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):731-736. PubMed ID: 30075973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.